AI assistant
Pharnext Regulatory Filings 2017
1594_rns_2017-09-05_b1a005fc-1342-4a18-9895-59ad7a5b4a59.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 5 September 2017 17:45
Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference
DGAP-News: Pharnext S.A. / Key word(s): Conference
05.09.2017 / 17:45
The issuer is solely responsible for the content of this announcement.
Pharnext to Present at Rodman & Renshaw 19 th Annual Global Investment Conference
Paris, France, 5:45pm, September 5, 2017 (CEST) – Pharnext SA (FR00111911287 – ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the Rodman & Renshaw 19 th Annual Global Investment Conference.
The presentation will take place as follows:
-
Date: Tuesday, September 12 th , 2017
-
Time: 5:30 pm EDT (11:30 pm CEST)
-
Venue: Lotte New York Palace Hotel in New York, New York
If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at [email protected] .
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY(TM). The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG(TM) offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Contacts:
| Pharnext Xavier Paoli Chief Commercial Officer [email protected] +33 (0)1 41 09 22 30 |
||
| Investor Relations (Europa) MC Services AG Anne Hennecke [email protected] +49 211 529252 22 |
Investor Relations (USA) Stern Investor Relations, Inc. Matthew Shinseki [email protected] +1 212-362-1200 |
Financial Communication (Frankreich) NewCap Emmanuel Huyn [email protected] +33 (0)1 44 71 20 40 |
| Media Relations (Europa) ALIZE RP Caroline Carmagnol Margaux Pronost [email protected] +33 (0)1 44 54 36 64 |
Media Relations (USA) Russo Partners Tony Russo Scott Santiamo [email protected] [email protected] [email protected] +1 212-845-4251 +1 718-344-5843 |
05.09.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de